RT Journal Article
SR Electronic
T1 Tripterygium glycosides as a potential treatment for CAR-T induced cytokine release syndrome: implication of monocyte depletion
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.22.20232801
DO 10.1101/2020.11.22.20232801
A1 Xu, Zuqiong
A1 Tian, Fang
A1 Chen, Biqing
A1 Kong, Xiangtu
A1 Dai, Xingbin
A1 Cao, Jiang
A1 Jiang, Pengjun
A1 Tan, Jianxin
A1 Lu, Lu
A1 Wang, Xiachang
A1 Lv, Qi
A1 Kang, Di
A1 Xu, Miao
A1 Hu, Yingying
A1 Yang, Aiping
A1 Wang, Qian
A1 Yang, Zhong-Fa
A1 Sun, Xuemei
A1 Ma, Leyuan
A1 Hu, Lihong
A1 Zhu, Xuejun
YR 2020
UL http://medrxiv.org/content/early/2020/11/27/2020.11.22.20232801.abstract
AB Background Cytokine release syndrome (CRS) is a potentially life-threatening complication of chimeric antigen receptor T (CAR-T) cell therapy. Recent studies indicated critical roles of macrophages and monocytes in CAR-T induced CRS. Here, we report rapid dissipation of CAR-T induced CRS in two patients after receiving Tripterygium glycosides (TG). Effects of triptolide, the major active component of TG, on macrophages and monocytes were examined in animal models.Methods Two patients with CRS after CAR-T cell therapy (for hematological malignancy) received TG (50 mg, p.o.). Flow cytometry analysis and single cell RNA sequencing (scRNAseq) were conducted to examine the effects of TG on immune cells. Potential effects of triptolide were also examined ex vivo using patient-derived monocytes, as well as in mice.Findings Rapid alleviation of fever and cytokine storm was observed within 72 hours after TG treatment. Blood concentration of triptolide ranged from 21 to 154 ng/mL during treatment. Flow cytometry and scRNAseq showed selective depletion of monocytes with minimal impact on CAR-T cells in both patients. In ex vivo experiments with patient-derived monocytes, triptolide dramatically inhibited the synthesis of pro-inflammatory cytokines (e.g., IL-6, IL-10, and IP-10). Triptolide also rapidly and selectively depleted peritoneal concanavalin A activated macrophages and monocytes in mice.Interpretation TG could be a promising treatment for CAR-T induced CRS, as well as other diseases with similar mechanisms, e.g., hemophagocytic lymphohistiocytosis and COVID-19. Our preliminary findings require further verification with properly designed clinical trials.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR-OIC-17013081,ChiCTR1900028098,ChiCTROIC-17011272Funding StatementThis study was supported in part by the Science and Technology Development Program of Jiangsu Province-Clinical Frontier Technology (grant Nos. BE2016809, BE2017639), the Nanjing Science and Technology Development Program (grant Nos. 201503011), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) (grant Nos. 035062002003c), and the development program of Jiangsu Provincial Hospital of Chinese Medicine (grant Nos.Y19030, Y19066).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been approved by Institutional Review Board of Affiliate Hospital of Nanjing University of Chinese Medicine.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request by emailing to zhuxuejun{at}njucm.edu.cn.